RecruitingPhase 2NCT04094090

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia


Sponsor

Goodman Eye Center

Enrollment

500 participants

Start Date

Oct 19, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing corneal cross-linking (CXL) for the treatment of ectatic disorders.


Eligibility

Min Age: 10 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates a new ultraviolet (UV) light system called PXL-Platinum 330 for corneal cross-linking — a procedure that strengthens the cornea to slow or stop the progression of keratoconus or other corneal thinning conditions. You may be eligible if: - You are 10 years old or older - You have keratoconus, post-surgical ectasia, or pellucid marginal degeneration confirmed by eye examination and imaging - Your cornea's thinnest point is at least 300 microns You may NOT be eligible if: - Your cornea is classified as normal on testing - Your cornea is thinner than 300 microns at the thinnest point - You have active corneal disease (e.g., herpes simplex, recurrent corneal erosion) - You are pregnant, planning pregnancy, or breastfeeding - You have a known allergy to study eye drops - You have a condition that prevents you from holding a steady gaze Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTPXL-330 Platinum device for crosslinking with Peschke riboflavin solution

Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea


Locations(1)

Goodman Eye Center

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04094090


Related Trials